The growth rate of vaccine industry recovers obviously, and the market prospect is worth looking forward to

[pharmaceutical network market analysis] according to the data, the global vaccine market scale has increased from 34.1 billion US dollars in 2014 to 49.4 billion US dollars in 2018 Driven by the increasing global demand for vaccination, the support of governments and international institutions, and the drive of research and development of new vaccines, it is estimated that the global vaccine market scale will exceed 58 billion US dollars in 2020 Therefore, with the favorable environment, China's vaccine industry has begun to usher in a vigorous development Some time ago, the performance forecast of the leading vaccine listed companies in 2019 came out one after another, from which we can see that the development of the vaccine industry improved significantly in the second half of 2019 For example, on January 9, Kangtai biology, a leading domestic vaccine company, issued a performance forecast for 2019 It is estimated that the company will achieve a net profit of RMB 550 million to RMB 590 million in the whole year, an increase of 26.24% to 35.42% compared with RMB 436 million in the same period of last year As can be seen from the data, the performance began to improve significantly in the second half of the year In fact, Kangtai biology is not the only leading vaccine company with good performance in 2019 On January 6, Hualan biology also said that the company expects to achieve a net profit of 1.253 billion yuan to 1.367 billion yuan in 2019, an increase of 10% to 20% year on year The performance growth mainly benefited from the stable growth of the company's blood products business and the large increase of sales revenue of the holding subsidiary's quadrivalent influenza vaccine On January 3, the annual performance forecast released by Zhifei biology showed that the company expected to achieve a net profit of 2.25 billion yuan to 2.54 billion yuan in 2019, an increase of 55% to 75% over the same period of last year Zhifei said that in 2019, the company continued to focus on vaccine and biological products research and development, production, sales, promotion, distribution and import vaccine agency, and its main business income, net profit and other important financial indicators had a better growth than the same period of last year At present, it has announced that the net profit of vaccine leading enterprises has mostly increased, and the performance is generally good Therefore, on the whole, although China's vaccine industry temporarily entered the adjustment period in the first half of 2019 after the vaccine event, it has shown signs of recovery in the second half of 2019 With the continuous fermentation of various driving factors, the future market prospect is still worth looking forward to At present, people's awareness and acceptance of vaccines are constantly improving With the continuous popularity of vaccination, as well as the attention of relevant policy guidance to "prevention of disease", the scale of China's vaccine market will be expanded In this regard, some insiders said that the long-term development of the industry lies in technological upgrading, while the short-term development is heavy product In terms of the vaccine growth path in the global mature market and the development stage of domestic vaccines and Chinese pharmaceutical industry, China's vaccine industry is catching up with the global market in terms of policies, patterns and products With the continuous investment of enterprises, it will enter a new round of growth cycle driven by heavy products In the future, domestic heavyweight products will mainly come from two aspects: one is from unit price to multi linked multi price vaccine (product upgrade), and the other is for emerging vaccines (product innovation) that have never been met In the short term, a number of new heavy-duty vaccine products are expected to be launched in China In the long run, the market opportunity of China's vaccine industry lies in technological innovation and product innovation Only when domestic enterprises increase R & D investment, and accelerate innovation, can they remain invincible in the future market competition.